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Abstract - Epilepsy is one of the leading neurological disorders and affects 1-2% of the world’s population. Generally, it 
is a result of an imbalance between excitatory and inhibitory phenomena in the central nervous system (CNS), but the 
mechanisms of its initiation and propagation still require further investigations. Experimental models represent one of the 
most powerful tools to better understand the mechanisms of epileptogenesis. Nitric oxide (NO) is gaseous molecule with 
pleiotropic physiological and pathological effects in almost all organ systems and intriguing biological relevance, especially 
in the CNS where it acts as a gaseous neurotransmitter. The role of NO in the generation of epilepsy is highly contradictory, 
since there is evidence of its anticonvulsive, as well as proconvulsive properties. Therefore, we will discuss in this review the 
involvement of NO-mediated signaling pathways in the mechanisms of epileptogenesis, taking into account the findings 
revealed in experimental studies on animal models of epilepsy.
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INTRODUCTION
Nitric oxide (NO) is a gaseous molecule with dis-
tinct  functions  in  almost  all  organ  systems  and 
intriguing  biological  relevance,  especially  in  the 
central nervous system (CNS). From the discovery 
of the endothelial-derived relaxing factor in 1980 
and its subsequent determination as NO (Furchgot 
and Zawadski, 1980; Murad, 1998), NO has become 
one of the leading research targets and the field of 
its research is one of the fastest growing areas in 
contemporary  biosciences.  Together  with  hydro-
gen sulfide (H2S) and carbon monoxide (CO), NO 
belongs to the family of gaseous transmitters (also 
called gasotransmitters). Their common character-
istics are as follows: a) small molecules of gas; b) 
freely permeable to membranes; c) endogenously 
and enzymatically generated in processes that can 
be  regulated;  d)  well-defined  physiological  func-
tions  at  physiologically  relevant  concentrations; 
e) their cellular effects may or may not be medi-
ated by second messengers (Wang, 2002). Beside its 
function as a vasorelaxant, NO displays pleiotropic 
physiological and pathological effects (Guix et al., 
2005). Due to its properties, NO plays a key role in 
a recently described form of interneuronal commu-
nication, characterized by the absence of synaptic 
contacts and lack of specific membrane receptors 
(Vizi, 2000). Although NO is involved in some ma-
jor physiological process in the CNS such as learn-1208 D. HRNČIĆ ET AL.
ing and memory through long-term potentiation, it 
could also contribute to a number of neurological 
disorders including epilepsy (Guix et al., 2005). Its 
role in the generation of epilepsy is highly contra-
dictory, since there is evidence of its anticonvulsive, 
as well as proconvulsive properties.
This review has focused on the contribution of 
NO-mediated  signaling  pathways  in  the  initiation 
and propagation of epilepsy and it is based on the 
findings of experimental studies on animal models 
of epilepsy. 
Epilepsy and its experimental models
Epilepsy is a chronic neurological disorder encom-
passing a diverse group of seizure disorders caused 
by a variety of morphological, cellular and molecular 
alterations of the brain primarily affecting the cere-
bral cortex and leading to recurrent epileptic seizures 
(Badway et al., 2009). Epileptogenesis, i.e. processes 
of alteration of a normal neuronal network into a 
network of synchronized hyperexcitable neurons, has 
been associated with an imbalance between inhibito-
ry (gamma-amininobutyric acid (GABA)-mediated) 
and excitatory (glutamate-mediated) neurotransmis-
sion systems, in favor of the latter (McCormick and 
Contreras, 2001; Dalby and Mody, 2001; Avoli et al., 
2005; Badway et al., 2009). 
In developed countries, the incidence of epilepsy 
is around 50 per 100,000 people per year (Duncan et 
al., 2006). Thus, it is one of the major health prob-
lems. Despite an extensive search for adequate thera-
py, epilepsy remains poorly controlled in almost 40% 
of the patients (Loscher, 2002). Therefore, a better 
understanding of epileptogenesis is the only way for 
the development of new antiepileptic treatments and 
strategies.
Experimental  models  represent  one  of  the 
most  powerful  tools  to  better  understand  the 
mechanisms  of  epileptogenesis.  A  number  of 
very useful chronic experimental models of epi-
lepsy that served to evaluate potential therapeutic 
treatments and drugs, has been developed and it 
is highly likely that no single model system could 
be useful for all types of epilepsy (Stanojlović and 
Živanović,  2004).  These  animal  models  involve 
experimental manipulation in which the epileptic 
condition is produced by different chemical com-
pounds or electrical stimulation. Among others, 
commonly used experimental epilepsy models are 
those induced by N-methyl-D-aspartate (NMDA), 
pentylenterazole, pilocarpine, kainic acid, 4-ami-
nopiridine, amygdala kindling, etc. (for review see 
Stanojlović and Živanović, 2004). In our labora-
tory,  different  animal  models  have  been  devel-
oped, including metaphit-induced audiogenic sei-
zures (Stanojlović et al., 2002, 2004, 2007; Hrnčić 
et al., 2006, 2008), lindane- (Vučević et al., 2008, 
Mladenović et al., 2007, Hrnčić et al., 2009) and 
homocysteine-induced  seizures  (Stanojlović  et 
al., 2009). We have shown that these experimental 
rat models of generalized epilepsy are suitable for 
the studies of epilepsy mechanisms and preclini-
cal evaluation of potential avenues in antiepileptic 
treatment (Rašić et al., 2009a, 2011a).
Lindane  (gamma-hexachlorocyclohexane), 
an organochloride extensively used as an insecti-
cide, pesticide and scabicide (Li, 1999), interacts 
with the picrotoxin site within the GABAA recep-
tor  chloride  channel  leading  to  epileptic  activity 
(Nyitrai et al., 2002). Seizures induced by lindane 
in rats represent an experimental model of gener-
alized epilepsy (Vučević et al., 2008). On the other 
hand, homocysteine is a sulfur-containing amino 
acid endogenously generated during the metabo-
lism of methionine (Hoffer, 2004). It has recently 
been recognized, together with its highly reactive 
thioester homocysteine thiolactone (Hct), as one 
of the most potent excitatory agents in the CNS 
(Jakubowski  2004;  Perla-Kajan,  2007;  Herrmann 
and  Obeid,  2011).  The  primer  mechanism  of  its 
convulsive properties has been assigned to the ac-
tivation of NMDA and group I metabotropic gluta-
mate  receptors  (Throen,  2005).  Stanojlović  et  al. 
(2009) showed recently that acute administration 
of Hct to adult rats significantly alters the neuro-
nal circuits, leading to epileptogenic activity in the 
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spike-and-wave discharges (SWD), and convulsive 
episodes in animal behavior. Hct-induced seizures 
are accepted as a suitable model of generalized epi-
lepsy in which the coexistence of convulsive and 
absence-like seizures has been proven (Rašić et al., 
2009b, 2011b).
The aforementioned experimental models of ep-
ilepsy have been extensively used to investigate the 
role of NO-mediated signaling pathways in the proc-
ess of epileptogenesis. 
Biosynthesis of NO
NO is produced from L-arginine by the activity of the 
family of enzymes known as NO synthases (NOS). 
Three different forms of NOS have been identified as 
a product of distinct genes. Neural (nNOS) and en-
dothelial NOS (eNOS) are Ca2+/calmodulin-depend-
ent  enzymes,  while  inducible  NOS  (iNOS)  shows 
Ca2+-independent  properties.  Mitochondrial  NOS 
(mtNOS) is actually an isoform of nNOS located in 
the inner mitochondrial membrane (Elfering et al., 
2002). Each NOS peptide consists of a C-terminal 
reductase domain and an N-terminal oxygenase do-
main that forms the active site of the enzyme (Hem-
mens and Mayer, 1998). Its catalytic activity depends 
on the cofactors nicotinamide adenine dinucleotide 
phosphate (NADPH), tetrahydrobiopteridin (BH4), 
flavin adenine dinucleotide (FAD), flavin mononu-
cleotide (FMN), oxygen (O2) and protoporphyrin Ix 
(Stuehr, 1999). 
Constitutive  isoforms  are  responsible  for  the 
synthesis  of  physiologically  vital  amounts  of  NO 
(Bredt  and  Snyder,  1990),  while  iNOS  produces 
high amounts of NO lasting hours or days (Aktan, 
2004). All three NOS isoforms are expressed in vari-
ous brain cells and may affect brain function. Neu-
rons produce NO mostly by the activation of nNOS 
(Knowles and Moncada, 1994), which is found in the 
cerebral cortex, hippocampus, corpus striatum and 
cerebellum, as well as in some ganglion cells of the 
autonomic nervous system (Zhou and Zhu, 2009). 
iNOS is found to be expressed in the brains of hu-
mans with epilepsy, as well as in some spontaneously 
epileptic  mice  (González-  Hernández  et  al.,  2000; 
Murashima, 2000). 
Pharmacological modulation of NO levels could 
be achieved through the application of NO donors, 
non-selective and selective NOS inhibitors. Of the 
donors, L-arginine, as an NO precursor, and sodium 
nitroprusside (SNP), have been used the most ex-
tensively in pharmacological studies of NO effects. 
N-nitro-L-arginine methyl ester (L – NAME) is a 
non-selective NOS inhibitor widely used to decrease 
NO levels. 7-nitroindazole and aminoguanidine are 
selective inhibitors of nNOS and iNOS, respectively, 
and are commonly used to investigate the role of 
nNOS and iNOS in brain functioning (Babbedge et 
al., 1993; Griffiths et al., 1993). 
Modulation of NO-signaling in experimental  
models of epilepsy
Numerous reports have indicated an anticonvulsive 
activity of NO in different experimental models of 
epilepsy. NOS inhibitors have been reported to in-
crease seizure severity induced by an intramygdaloid 
injection of kainate, and to increase the amygdala-
kindling rate (Rondouin et al., 1992, 1993). It has 
also been found that L-arginine (150-600 mg/kg, 
i.p.) increased dose-dependently the dose of kain-
ate necessary to produce clonic convulsions in 50% 
of the animals (Przegalinski et al., 1994). Results 
obtained on the status epilepticus induced by the 
systemic administration of kainic acid are consist-
ent with the above-mentioned data (Alabadi et al., 
1999). L-NAME caused an increase in both dura-
tion and seizure severity in a mice model of gener-
alized epilepsy induced by intracerebroventricular 
(i.c.v.)  administration  of  NMDA  (Buisson  et  al., 
1993), while NOS inhibition has also been reported 
to potentiate the seizures induced by an i.c.v. injec-
tion of quinolinate to rats (Haberny et al., 1992). 
NOS  inhibitors  also  facilitated  focal  seizures  in-
duced by aminopyridine in rats (Boda and Szente, 
1996). Tsuda et al (1997) showed an aggravation of 
DMCM (full inverse agonist of GABAA)-induced 
seizures by NOS inhibitors in mice. The anticonvul-
sive role of NO has also been showed in picrotoxin-1210 D. HRNČIĆ ET AL.
induced convulsions (Paul and Ekambaram 2003; 
Paul et al., 2002; Paul and Ekambaram, 2005) and 
penicillin-induced epileptiform activity in rats (Ma-
rangoz and Bagirici, 2001; Ayyildiz et al., 2007). The 
involvement of NO in convulsions induced by nico-
tine in mice has been reported (Tutka et al 2007). 
L-arginine protected genetically epilepsy-prone rats 
and DBA/2 mice from sound-induced convulsions 
(Smith et al., 1996).
In the case of pentylenterazole (PTZ), a GABAA 
-mediated convulsive agent, NOS inhibitors may 
inhibit seizures (Osonoe et al., 1994; Hara et al., 
1996; Kaputlu and Uzbay, 1997; Bashkatova et al., 
2000; Han et al., 2000), although several reports 
have  indicated  no  effect  on  PTZ-induced  sei-
zures (Przegaliñski et al., 1996; Urbanska et al., 
1996; Han et al., 2000). However, a recent study 
has  revealed  that  mice  lacking  the  nNOS  gene 
(nNOS-/-) exhibited severe seizures following the 
administration of a sub-convulsive dose of PTZ 
and that a convulsive dose was lethal in all of the 
mice, following tonic convulsions (Itoh and Wa-
tanabe, 2009). Treatment of pilocarpine-induced 
seizures  with  NOS  inhibitors  has  been  reported 
to augment (Del-Bel et al., 1997; Starr and Starr, 
1993), to inhibit (Van Leeuwen et al. 1995) or to 
be without effects (Noyan et al., 2007) on the epi-
leptic activity. In the lithium-pilocarpine-induced 
seizure model, L-arginine at a dose of 300 mg/kg 
has been found to act as an anticonvulsant (Noyan 
and Gulec, 2000). 
NO has been reported as a proconvulsant agent 
in several seizure models (Bagetta et al., 1992; De 
Sarro et al.,1991, 1993; Mollace et al., 1991; Urbanska 
et al., 1996; Proctor et al., 1997; Lu et al 1998; Borow-
icz et al., 2000; yasuda et al., 2001; Sardo et al., 2006). 
In line with this, in a model of “maximal dentate ac-
tivation” (MDA), the inhibition of nNOS caused an 
increase of the MDA onset time and a decrease of 
MDA-induced spiking afterdischarges duration. On 
the contrary, the administration of L-arginine caused 
opposite effects: a decrease in the MDA onset time 
and an increase of MDA and afterdischarges dura-
tion (Ferraro et al., 2004).
NO in an experimental model of homocysteine  
thiolactone-induced epilepsy: mechanisms of its  
anticonvulsive properties
Recently, we showed that the systemic administra-
tion of increasing doses of L-arginine in a dose-de-
pendent manner significantly decreased seizure in-
cidence and the prolonged latency time to the first 
seizure elicited by a convulsive dose of Hct (Hrnčić 
et al., 2010). On the other hand, pretreatment with 
L-NAME,  in  a  dose-dependent  manner,  increased 
seizure  incidence  and  severity  and  shortened  the 
latency time to the first seizure following injection 
with a sub-convulsive dose of Hct. In the same study, 
L-arginine  decreased  and  L-NAME  increased  the 
median number of SWD per rat, while the duration 
of  individual  SWD  was  not  altered.  These  results 
showed  the  functional  involvement  of  NO  in  the 
Hct-induced convulsive activity. 
Furthermore, the involvement of nNOS in Hct-
induced seizures was determined using a pharma-
cological inhibition of this enzyme by 7-nitroinda-
zole  (Hrnčić  et  al.,  2012).  Congruent  results  with 
those obtained using non-selective inhibition were 
obtained. Namely, systemic administration of 7-ni-
troindazole,  a  selective  nNOS  inhibitor,  showed  a 
tendency to increase seizure incidence, decrease la-
tency time to the first seizure, increase the number of 
seizure episodes per rat and increase the severity of 
seizures induced by Hct in rats. The contribution of 
iNOS-derived NO in epileptogenesis caused by Hct 
was  recently  demonstrated  using  aminoguanidine 
(Hrnčić et al., 2012).
The anticonvulsive activity of NO in Hct-induced 
seizures could be explained by several mechanisms, 
including the relationship of NO with the NMDA 
and GABA receptors.
NO could modulate the NMDA receptor activity 
by interacting with the -SH group of the NMDA re-
dox modulatory site via the process of S-nitrosylation. 
This results in the downregulation of this receptor 
complex (Lipton et al., 1993), preventing the neuro-
toxic effects of an excessive Ca2+ influx during homo-NO AND ExPERIMENTAL EPILEPSy 1211
cysteine-induced  “overstimulation”  of  NMDA  and 
mGluRs I receptors. Moreover, in cultured rat corti-
cal neurons Kim et al. (1999) demonstrated that NO 
could ameliorate the effects of adverse excitotoxicity 
by S-nitrosylation. In addition, it should be pointed 
out that NO induces the reduction of glutamate by 
the activation of the glial cells (Nanri et al., 1996). 
The co-localization of NOS and GABA has been 
demonstrated in experimental studies (Wang et al., 
1997). Paul and Ekambaram (2005) suggested that 
NO inhibits GABA transaminase. The basal NO lev-
els induce depression, while high concentrations of 
NO increase the GABA release (Getting et al., 1996). 
This could explain the anticonvulsive NO properties. 
Unlike to homocysteine, which increases oxidative 
stress by the production of reactive oxygen species 
(Ramakrishnan, 2006), NO can act as a neural pro-
tector, due to the formation of S-nitroso-L-glutath-
ione, an antioxidant (Rauhala et al., 1998).
It is known that homocysteine and Hct can cause 
neurodegeneration, synaptic dysfunction and neuro-
nal death by promoting DNA damage and the activa-
tion of apoptotic signaling (Mattson and Shea, 2003), 
which contribute to the observed high lethality upon 
Hct  administration  in  higher  doses.  Inhibition  of 
caspases  by  S-nitrosylation  (Mannick  et  al.,  1999) 
and the expression of cytoprotective genes (Hao et 
al., 1999) by NO could explain the neuroprotective 
effects of NO demonstrated in our experiments by a 
reduction in lethality (Hrnčić et al., 2010). 
NO in an experimental model of lindane-induced  
seizures: mechanisms of its proconvulsive properties
Investigating the role of NO in lindane seizures, we 
showed that the systemic application of L-arginine 
in a dose-dependent manner significantly increased 
seizure  incidence  and  severity  and  shortened  the 
latency time to the first seizure elicited by a sub-
convulsive dose of lindane (Hrnčić et al., 2011). On 
the contrary, pretreatment with L-NAME decreased 
seizure  incidence  and  severity,  and  prolonged  the 
latency time to the first seizure following injection 
with a convulsive dose of lindane. Hence, the study 
elucidated the functional involvement of NO in lin-
dane convulsive activity, i.e. it revealed NO as an en-
dogenous mediator in this seizure model. 
No signs of ictal activity were recorded in the 
EEG of rats treated with the highest applied doses of 
L-arginine or L-NAME (Hrnčić et al., 2010, 2011). 
Contrary findings to ours have been reported by Fer-
raro et al. (1999), showing that NOS inhibition elic-
ited ictal activity in rat brain in the form of spikes, 
polyspikes and spike and waves. We showed an in-
crease in the number and duration of the ictal peri-
ods in the EEG of rats receiving L-arginine prior to 
lindane and a decrease of this number in rats pre-
treated with L-NAME (Hrnčić et al., 2011). These re-
sults support the proconvulsive role of NO in lindane 
seizures. 
Different mechanisms could be involved in the 
proconvulsant  effects  of  NO  in  lindane  seizures. 
Increased  levels  of  NO  activate  guanylate  cyclase 
(GC) and markedly increase the production of cyclic 
guanosine-3,5-monophosphate (cGMP), which, as a 
secondary messenger, stimulates protein kinase G, 
phosphorylates the GABAA receptor and inactivates 
it  (Robello  et  al.,  1996).  Lindane  evokes  seizures 
mainly through the blockade of the GABAA receptor 
complex (Anand et al., 1998; Nyitrai et al., 2002; Su-
nol et al., 1997). Therefore, the proconvulsant effect 
of NO could be explained by its cooperation with lin-
dane in GABAA receptor inactivation. NO increases 
Ca2+ intracellular levels (Willmott et al., 2000, Horn 
et al., 2002) and by this mechanism could potentiate 
the activity of lindane in Ca2+ mobilization. The en-
gagement of excitatory amino acids has been proven 
in lindane seizures (Blaszczak et al., 1998), while NO 
is documented to enhance the release of glutamate, 
the  main  excitatory  neurotransmitter,  in  different 
brain regions according to the study of Marcoli et al. 
(2006). Therefore, the synergistic effect of NO and 
lindane is also possible in this activity. 
CONCLUSIONS
Although numerous attempts have been made to 
precisely define the role of NO in the mechanisms 1212 D. HRNČIĆ ET AL.
of epileptogenesis, this remains an open question. 
We demonstrated both the anticonvulsive and pro-
convulsive properties of NO-signaling in different 
experimental models of epilepsy and reviewed the 
possible mechanisms of its activity. Observed dif-
ferences in the effects of NO could, at least in part, 
be explained by the diversity of the molecules in-
teracting with NO, the seizure models employed, 
the type and dose of drugs used in order to modify 
brain NO levels and the strain of animal. The grow-
ing evidence for the involvement of other members 
of the gaseous neurotransmitter family (H2S  and 
CO)  in  the  process  of  epileptogenesis  and  their 
multiple interactions with NO will contribute to a 
better understanding of the NO-mediated regula-
tion of neural excitability. 
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